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,f][1,4]-oxAbstract In the present study, a series of new substituted N-11-(40-N-aryl carboxamido/N-(aryl)-
a-phenyl-acetamido-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives were designed on a revised
structural model, length and nature of linker and introduced aryl group. All the compounds
(MJ1–MJ12) were synthesized by economical route and conﬁrmed by IR, 1H NMR, and mass spec-
tral analyses. The antipsychotic potentialities of the synthesized derivatives were evaluated in mice
by catalepsy and foot sock induced aggression. The present study demonstrates signiﬁcant antipsy-
chotic activity for most of the compounds from series. Compounds MJ-1, MJ-3 and MJ-4 were
found to be potent antipsychotic compounds of the series at 5 mg/kg dose level when compared
with the reference drug clozapine.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Schizophrenia is one of the most widespread psychiatric disor-
ders and approximately 1.5–2% of the world’s population suf-
fers from severe symptoms occupying more than half of the
beds in psychiatric clinics (The World Health Report, 2001).
Currently many drugs are available for the treatment of psy-
chosis. Ever since antipsychotics were introduced it has been459367; fax:+91 2563255189.
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azepine derivatives. Arabian Journalobserved that patients are liable to suffer from drug-induced
extrapyramidal symptoms such as Parkinsonism, acute dys-
tonic reactions, akathisia, tardive dyskinesia and tardive dysto-
nia (Chakrabarti et al., 1980; Work group on schizophrenia,
1997). The introduction of the dibenzodiazepine antipsychotic
agent clozapine (8-chloro-11[4-methyl-1-piperazinyl]-5H-
dibenzo-[b,e][1,4] diazepine) was an important development
in the pharmacotherapy of schizophrenia (Burki et al., 1975;
Sayers et al., 1975). Preclinical and clinical investigations have
shown that clozapine has properties different from those of
classic neuroleptic agents, as well as a substantial therapeutic
advantage (Kane et al., 1981; Lieberman et al., 1986;
Lieberman et al., 1989). Clozapine was found to be one of
the better choices for the treatment of refractory
schizophrenia. Unlike classic neuroleptic agents, clozapine
did not cause Parkinsonism, dystonia, or tardive dyskinesia,ing Saud University.
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spite the promise of clozapine, its use has been limited by its
propensity to cause agranulocytosis (Alvir et al., 1993).
The progress made in the area of QSAR and bioisosterism
has opened an avenue to get better and safer drugs. Loxapine
and Clozapine belong to the class of dibenzoxazepine and dib-
enzodiazepine, respectively and they differ in pharmacody-
namic proﬁle (Wagh et al.,2007; Wagh et al., 2005). The
Loxapine like drugs e.g. Clothiapine, Metiapine, and Zotepine;
have an electronegative group at carbon-2 position that is rel-
atively close to the side chain nitrogen and showed extrapyra-
midal side effects. On the other hand Clozapine like drugs e.g.
Clozapine, Fluperlapine and Olanzapine all either lack a ring
substituent or have an electronegative group at C-8 position,
much away from side chain nitrogen (Wagh et al., 2007).
Therefore, Clozapine has thus inspired a search for additional,
safer, ‘atypical’ agents with antipsychotic activity and low risk
of extrapyramidal side effects. Pharmacological investigation
of series of clozapine analogues revealed that optimal length
of the hydrocarbon linker between N40 and the introduced aryl
system (phenyl) was two to four atoms (Capuano et al., 2003).
Both Clozapine and Loxapine on N-demethylation (at N4 of
piperazine) produce less active or toxic metabolite (Capuano
et al., 2003). Consequently, keeping the view of blocking the
N-demethylation metabolism of Clozapine and Loxapine in
our mind we have blocked N4 demethylation by substituting
alkyl or aryl acetamido group at N4 of piperazine so as to in-
crease half-life of drug and reduce side effects. Keeping this
view in mind and continuation of our research toward devel-
opment of potent antipsychotic agents (Wagh et al., 2007),
herein, we have incorporated an N-aryl carboxamido/N-
(aryl)-a-phenyl-acetamido-piperazinyl substituted at N4 of
piperazine in dibenzoxazepine derivatives to improve their
antipsychotic potential. Several synthetic routes were reported
for the synthesis of tricyclic ring, Stutton et al. reported syn-
thesis using 2-chloro nitro benzene and phenol in the presence
of copper followed by reduction, phosgenation and cyclization
(Stutton, 1969). In other route, 2-amino diphenyl ether was re-
acted with ethyl chloroformate followed by phosphorous oxy-
chloride (Smits et al., 2006). We have tried for a new route of
synthesis using 2-ﬂuoro nitrobenzene and methyl salicylate in
presence of potassium carbonate followed by reduction with
raney nickel and cyclization at 150 C. In present work we
have not only developed new route of synthesis using commer-
cially available raw material but also achieve good yield with
better antipsychotic potency of the target derivatives.
2. Methods and materials
All solvents and chemicals used in the synthesis were procured
from commercial suppliers and puriﬁed whenever necessary.
Progress of the reaction was monitored by TLC using Chloro-
form:acetone (9:1) system. The o-ﬂuoro nitrobenzene, methyl
salicylate, dioxane, potassium carbonate, methanol, pipera-
zine, xylene, phosphorus oxychloride and a-chloro phenylace-
tic acid were procured from Rankem labs. Raney Ni and
triphosgene were procured from sampro organic research
lab. Melting points (mp) were determined using Veego micro-
processor based programmable melting point apparatus, in
open capillaries and were uncorrected. Infrared spectra were
scanned on Shimadzu 8400S FTIR spectrometer with sodiumPlease cite this article in press as: Jain, M.S., Surana, S.J. Synthesis and evaluatio
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives. Arabian Journalchloride optics and are measured in cm1. 1H NMR spectra
were recorded on Varian Mercury YH-300 MHZ (Gemini),
Bruker-500 MHz and Varian Unity-400 MHz spectrometer.
All experiments were carried out in CDCl3 as solvent and
1H chemical shift of the solvent was used as a secondary refer-
ence and referred to the TMS signal from the usual relation-
ship; the values of the chemical shift (d) are given in ppm.
Mass spectra were recorded on Jeol SX 102/Da-600 mass spec-
trometer, FAB gas at 10 kV accelerating voltage using a direct
inlet system. FAB mass spectra were recorded at room temper-
ature. Gas Chromatograms were recorded on Chemito-8610
HR using OV-101 column and B.P. 5 capillary column with
0.5 l ﬁlm thickness.
3. Synthesis
3.1. Synthesis of 2-nitro-20-methyl diphenyl ether carboxylate
(3)
A mixture of o-Fluoro nitrobenzene (10 gm, 0.070 mol), anhy-
drous potassium carbonate (14.7 g, 0.1066 mol) and methyl
salicylate (16.2 g, 0.1066 mol) was transferred in a 500 ml
round bottomed ﬂask, equipped with a sealed mechanical stir-
rer and a reﬂux condenser and contents were reﬂuxed in diox-
ane for 10 h. The reaction was monitored by GC. The reaction
mixture was dumped in water, extracted with toluene, the ex-
tract washed with 5% solution of sodium hydroxide. Toluene
was then distilled off to give thick liquid of 2-nitro-20-methyl
diphenyl ether carboxylate. Yield = 18 g (93%).
3.2. Synthesis of 2-amino-20-methyl diphenyl ether carboxylate
(4)
To a 2-nitro-20-methyl-diphenyl ether carboxylate (3) (18 g,
0.066 mol) was added 100 ml of methanol followed by the
addition of 1 g of Raney nickel, in a stainless steel hydrogena-
tion bottle and the reaction mixture was hydrogenated at
70 psi pressure, the reaction monitored by TLC. The catalyst
was ﬁlter and methanol was distilled-off under reduced pres-
sure to get the desired product, almost pure 2-amino-20-meth-
yldiphenyl ether carboxylate, Yield = 13.5 g (82%).
3.3. Synthesis of 11-Oxadibenz[b,f][1,4] oxazepine (5)
In a 100 ml round bottomed ﬂask, 2-amino-20-methyldiphenyl
ether carboxylate (4) (10 g, 0.041 mol), 50 ml dimethyl form-
amide, and 0.5 ml sulfuric acid were added and reﬂuxed for
15 h, the reaction was monitored by TLC. After the comple-
tion of reaction, it was cooled to room temperature and
dumped in 200 ml water. Off-white colored precipitate was ﬁl-
tered and dried. m.p. 210–212 C. Yield = 6.8 g (79%).
3.4. 11-chloro-dibenz[b,f][1,4] oxazepine (6)
In a 500 ml round bottomed ﬂask, 11-oxo-dibenzo [b,f][1,4] oxa-
zepine (5) (5 g, 0.023 mol), 50 ml POCl3 and 1 g N,N-dimethyl
aniline were mixed and reﬂuxed for 18 h. The excess POCl3
was distilled out under vacuum and the residue was extracted
with toluene (2 · 50 ml). The toluene extract was washed with
cold water (2 · 100 ml) to remove the traces of POCl3 and driedn of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-
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reduced pressure; residue was distilled under high vacuum and
yielded the pale yellow liquid, 11-chloro dibenzoxazepine
b.p.160–162 C (2 mm/Hg). Yield = 3.25 g (60%).
3.5. Synthesis of 11-piperazinyl-dibenz[b,f][1,4] oxazepine (7)
In a 100 ml round bottomed ﬂask, equipped with a condenser
and mechanical stirrer, anhydrous piperazine (3.3 g,
0.038 mol), and 30 ml xylene were placed. Mixture was heated
to 70–80 C and a solution of 11-chloro dibenzoxazepine (6)
(3 g 0.013 mol) in 20 ml xylene was added with stirring within
30 min and contents were further reﬂuxed for 5 h, then the
reaction mixture was cooled and dump in 100 ml water. Or-
ganic layer was separated and washed with water (2 · 50 ml)
to remove excess of piperazine. Xylene was distilled off under
vacuum; afforded, 11-piperazinyl dibenzoxazepine and was
further puriﬁed by column chromatography. m.p. 184–
186 C. Yield = 3 g (92%) IR cm1 3065 (–NH), 2893
(–CH), 1597 (C‚N), 1244 (C–O–C). 1H NMR d: 2.30 (s,
1H, NH), 3.80–3.50 (s, 8H, 4-CH2), 7.30–7.10 (m, 5H,
Ar–H), 7.40–7.35(d, 1H, Ar-H), 7.50–7.44(t, 1H, Ar-H), M/S
m/e: 279, 210, 194, 85.
3.6. Synthesis of aryl isocyanates (8a–e)
3.6.1. The following general procedure was adopted for the
synthesis of all isocyanates
In a 250 ml round bottomed ﬂask, equipped with a condenser
and dropping funnel, a mixture of p-toludine hydrochloride
(3 gm, 0.020 mol) and 50 ml xylene was heated. When the mix-
ture boiled, a solution of triphosgene (6.16 gm, 0.020 mol) in
30 ml xylene was added slowly using dropping funnel with
dip tube. As reaction was forwarded p-toludine hydrochloride
dissolved, after the complete addition of triphosgene solution
reﬂux was continued for further 30 min. Excess of toluene
was distilled and p-tolyl isocyanate was obtained by high vac-
uum distillation (10 mm Hg). p-Tolyl isocyanate was packed in
a bottle by ﬂushing with nitrogen. Yield = 2.3 g (85%).
3.7. Synthesis of substituted N-aryl-a-chlorophenylacetamides
(9a–e)
3.7.1. The following general procedure was adopted for the
synthesis of all the N-aryl-a-chlorophenylacetamides
In a 100 ml round bottomed ﬂask equipped with a stirrer and
condenser, o-chloro aniline (2.25 gm, 0.02 mol), tri-ethyl amine
(3.0 gm, mole) and 30 ml dioxane were placed and cooled to
0 C. The solution of a-Chlorophenyl acetyl chloride
(3.76 gm, 0.02 mol) in 20 ml dioxane was added drop wise with
stirring (During addition the temperature was maintained be-
tween 0 C and 10 C). After complete addition the mixture
was stirred for further 10 h at room temperature. The reaction
mixture was dumped in cold water and solid was ﬁltered and
dried. m.p. 130–132 C C, Yield = 3.7 g (78%).
3.7.2. Synthesis of 11-(40-N-phenyl carboxamido)–piperazinyl)-
dibenz[b,f][1,4]-oxazepine derivatives (MJ1)
In a 50 ml round bottomed ﬂask, 11-(Piperazinyl)-di-
benz[b,f][1,4]-oxazepine(7) (2.8 gm, 0.010 mol) was dissolvedPlease cite this article in press as: Jain, M.S., Surana, S.J. Synthesis and evaluatio
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives. Arabian Journalin 20 ml xylene and heated to 50 C C. Phenylisocyanate
(1.19 gm, 0.010 mol) was added dropwise, immediately product
was precipitated out. After complete addition (30–45 min) the
solid was ﬁltered off and dried. The product was recrystallized
from dilute hydrochloric acid (5%, 25 ml), solution was ﬁltered
and neutralized to pH 7 by dilute ammonia. Product was ﬁltered
and puriﬁed through alumina column eluted by chloroform.
m.p. 172–174 C. Yield = 2 g (51.70%). IR cm1 3327 (–NH),
1678 (C‚O), 1573(–NH), 1H NMR d: 2.91 (t, 4H, 2CH2),
3.61 (t, 4H, 2CH2), 6.15 (s, 1H, NH), 7.3–6.8 (m, 11H, Ar-H),
7.53–7.45 (d, 2H, Ar-H), 13C NMR d: 46.9, 50.2, 109.5, 117.4,
121.2, 124.8, 126.7, 129.4, 130.1, 136.9, 142.6, 148.7, 151.1,
155.2,171.2 m/z 398 (M+), 279, 209, 85.
3.7.3. Synthesis of 11-(40-N-(2-methylphenyl)-carboxamido)-
piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives (MJ2)
In a 50 ml round bottomed ﬂask, 11-(Piperazinyl)-di-
benz[b,f][1,4]-oxazepine(7) (2.8 gm, 0.010 mol) was dissolved
in 20 ml xylene and heated to 50 C C. Then, o-tolylisocyanate
(1.33 gm, 0.010 mol) was added drop wise, immediately prod-
uct was precipitated out. m.p. 164–66 C. Yield = 2.4 g (58%).
IR cm1: 3273 (–NH), 1653 (C‚O), 1593 (–NH), 1H NMR d:
2.32 (s, 3H, CH3), 2.82 (t, 4H, 2CH2), 3.48 (t, 4H, 2CH2), 6.0
(s, 1H, NH), 7.1–6.8 (m, 7H, Ar-H), 7.35–7.2 (m, 3H, Ar-H),
7.58–7.42 (d, 2H, Ar-H), 13C NMR d: 15.6, 48.2, 54.3, 105.2,
109.5, 115.3, 121.8, 123.1, 125.7, 128.3, 130.7, 146.5, 151.2,
155.8, 155.3, 172.9 m/z 413(M+1), 412(M), 307, 280, 194.
3.7.4. Synthesis of 11-(40-N-(4-methylphenyl)-carboxamido)–
piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives (MJ3)
In a 50 ml round bottomed ﬂask, 11-(Piperazinyl)-di-
benz[b,f][1,4]-oxazepine(7) (2.8 gm, 0.010 mol) was dissolved
in 20 ml xylene and heated to 50 C. Then p-tolylisocyanate
(1.33 gm, 0.010 mol) was added drop wise, immediately prod-
uct was precipitated out. m.p. 210–12 C. Yield = 2.6 g
(63.70%). IR cm1: 3425 (–NH), 1680 (C‚O), 1588 (–NH),
1H NMR d: 2.14 (s, 3H, CH3), 2.91 (t, 4H, 2CH2), 3.61 (t,
4H, 2CH2), 6.2 (s, 1H, NH), 7.2–6.9 (m, 8H, Ar-H), 7.5–7.3
(m, 4H, Ar-H), 13C NMR d: 22.5, 43.9, 47.8, 110.2, 115.3,
119.4, 125.8, 128.5, 129.9, 131.3, 138.2, 144.3, 149.1, 154.8,
158.3, 169.8 m/z 413(M+1), 412(M), 307, 280, 194.
3.7.5. Synthesis of 11-(40-N-(4-chlorophenyl)-carboxamido)–
piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives (MJ4)
In a 50 ml round bottomed ﬂask, 11-(Piperazinyl)-di-
benz[b,f][1,4]-oxazepine(7) (2.8 gm, 0.010 mol) was dissolved
in 20 ml xylene and heated to 50 C. Then p-chlorophenylisocy-
anate (1.53 gm, 0.010 mol) was added drop wise, immediately
product was precipitated out. m.p. 234–36 C. Yield = 2.39 g
(55.30%). IR cm1: 3358 (–NH), 1653 (C‚O), 1593(–NH),
1H NMR d: 2.95 (t, 4H, 2CH2), 3.66 (t, 4H, 2CH2), 6.32 (s,
1H, NH), 7.19–6.6 (m, 8H, Ar-H), 7.55–7.35 (m, 4H, Ar-H),
13C NMR d: 45.7, 51.4, 108.5, 119.3, 122.3, 124.7, 126.3,
128.4, 130.9, 137.9, 146.3, 149.6, 154.1, 158.4, 174.2 m/z 434,
432(M), 307, 292, 237, 194.
3.7.6. Synthesis of 11-(40-N-(4-methoxyphenyl)-carboxamido)–
piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives (MJ5)
In a 50 ml round bottomed ﬂask, 11-(Piperazinyl)-di-
benz[b,f][1,4]-oxazepine(7) (2.8 gm, 0.010 mol) was dissolvedn of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-
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isocyanate (1.49 gm, 0.010 mol) was added drop wise, immedi-
ately product was precipitated out. m.p. 202–04 C.
Yield = 2.9 g (67.5%). IR cm1: 3385 (–NH), 1653 (C‚O),
1593(–NH), 1H -NMR d: 3.12 (s, 3H, CH3), 3.43 (t, 4H,
2CH2), 3.95 (t, 4H, 2CH2), 5.8 (s, 1H, NH), 7.3–6.5 (m, 8H,
Ar-H), 7.57–7.48 (m, 4H, Ar-H), 13C NMR d: 47.9, 49.3,
57.4, 110.4, 118.2, 122.4, 124.5, 127.7, 130.3, 132.1, 136.4,
138.7, 147.2, 148.8, 152.5, 155.8, 171.4 m/z 428(M), 307, 279,
210.
3.7.7. Synthesis of 11-(40-N-(2,5-dichlorophenyl)-
carboxamido)–piperazinyl)-dibenz[b,f][1,4]-oxazepine
derivatives (MJ6)
In a 50 ml round bottomed ﬂask, 11-(Piperazinyl)-di-
benz[b,f][1,4]-oxazepine(7) (2.8 gm, 0.010 mol) was dissolved
in 20 ml xylene and heated to 50 C. Then 2, 5-dichlorophen-
ylisocyanate (1.87 gm, 0.010 mol) was added drop wise, imme-
diately product was precipitated out. m.p. 262–64 C.
Yield = 3.2 g (70.50%). IR cm1: 3421 (–NH), 1604 (C‚O),
1103(–NH), 1H NMR d: 3.2 (t, 4H, 2CH2), 3.76 (t, 4H,
2CH2), 6.12 (s, 1H, NH), 7.33–6.5 (m, 7H, Ar-H), 7.58–7.46
(m, 4H, Ar-H), 13C NMR d: 45.7, 47.8, 112.9, 117.8, 123.1,
124.8, 127.8, 131.5, 132.9, 135.2, 136.5, 138.2, 142.3, 148.4,
151.2, 156.7, 168.2 m/z 469, 467, 465(M), 307, 237, 194.
3.7.8. Synthesis of 11-(40-(N-phenyl-a-phenyl acetamido)-
piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives (MJ7)
In a 100 ml round bottomed ﬂask equipped with reﬂux con-
denser, a solution of 11-(piperazinyl)-dibenz[b,f][1,4]-oxaze-
pine(7) (2.8 gm, 0.010 mol) and tri-ethyl amine (1.5 gm,
0.015 mol) in 30 ml dioxane was taken. The reaction mixture
was heated to reﬂux and a solution of N-phenyl-a-chloro-
phenyl acetamide (2.45 gm, 0.01 mol) in 20 ml dioxane was
added with stirring. The mixture was reﬂuxed for 6–8 h and
the reaction was monitored by TLC. It was cooled to room
temperature and dumped in 200 ml ice cold water. The precip-
itated product was ﬁltered and dried. It was recrystallized from
aqueous methanol. m.p. 180–82 C. Yield= 2.80 g (57%). IR
cm1: 3410 (–NH), 1690 (C‚O), 1588 (–NH), 1H -NMR d: 2.2
(s, 1H, CH), 2.62 (s, 4H, 2CH2), 3.6 (s, 4H, 2CH2), 5.1(s, 1H,
NH), 7–6.8 (m, 4H, Ar-H), 7.16 (s, 5H, Ar-H), 7.24–7.3 (d, 4H,
Ar-H), 7.42–7.36 (m, 4H, Ar-H), 13C NMR d: 47.4, 49.8, 67.4,
110.2, 115.7, 119.5, 121.8, 123.7, 124.7, 125.2, 127.4, 129.4,
131.5, 133.4, 135.1, 136.9, 138.2, 145.2, 151.4, 157.2, 159.3,
172.3, m/z 489(M+1), 368, 263, 194.
3.7.9. Synthesis of 11-(40-(N-(2-methylphenyl)-a-phenyl
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives
(MJ8)
A solution of 11-(piperazinyl)-dibenz[b,f][1,4]-oxazepine (7)
(2.8 gm, 0.010 mol) and tri-ethyl amine (1.5 gm, 0.015 mol) in
30 ml dioxane was taken. The reaction mixture was heated
to reﬂux and a solution of N-2-methylphenyl-a-chlorophenyl
acetamide (2.59 gm, 0.01 mol) in 20 ml dioxane was added
with stirring. m.p. 208–10 C. Yield= 2.25 g (45%). IR
cm1: 3378 (–NH), 1680 (C‚O), 1590 (–NH), 1H -NMR d:
2.3 (s, 1H, CH), 2.45 (s, 3H, CH3), 2.75 (s, 4H, 2CH2), 3.7
(s, 4H, 2CH2), 5.3 (s, 1H, NH), 7.1–6.8 (m, 4H, Ar-H), 7.12Please cite this article in press as: Jain, M.S., Surana, S.J. Synthesis and evaluatio
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives. Arabian Journal(s, 5H, Ar-H), 7.34–7.28 (d, 4H, Ar-H), 7.52–7.4 (m, 4H, Ar-
H), 13C NMR d: 16.3, 46.5, 50.4, 65.3, 111.5, 117.8, 120.5,
121.4, 123.2, 124.3, 125.1, 126.8, 127.3, 129.4, 133.9, 135.2,
136.4, 137.3, 138.8, 142.7, 149.1, 156.4, 160.1, 174.7, m/z
503(M+1), 368, 278, 263, 194.
3.7.10. Synthesis of 11-(40-(N-(4-methylphenyl)-a-phenyl
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives
(MJ9)
A solution of 11-(piperazinyl)-dibenz[b,f][1,4]-oxazepine (7)
(2.8 gm, 0.010 mol) and tri-ethyl amine (1.5 gm, 0.015 mol) in
30 ml dioxane was taken. The reaction mixture was heated
to reﬂux and a solution of N-4-methylphenyl-a-chlorophenyl
acetamide (2.59 gm, 0.01 mol) in 20 ml dioxane was added
with stirring. m.p. 202–04 C. Yield= 2.75 g (55.40%). IR
cm1: 3368 (–NH), 1661 (C‚O), 1589 (–NH), 1H NMR d:
2.2 (s, 1H, CH), 2.23 (s, 3H, CH3), 2.67 (t, 4H, 2CH2), 3.63
(s, 4H, 2CH2), 5.7 (t, 1H, NH), 7.1–6.9 (m, 4H, Ar-H), 7.19
(s, 5H, Ar-H), 7.28–7.2 (d, 4H, Ar-H), 7.4–7.3 (m, 4H, Ar-
H), 13C NMR d: 26.2, 47.2, 51.5, 68.4, 112.8, 118.2, 120.4,
121.8, 122.9, 123.4, 125.5, 126.3, 127.3, 129.7, 132.4, 134.7,
136.8, 137.9, 139.2, 143.4, 148.2, 158.1, 160.4, 173.9, m/z
503(M+1), 502, 368, 278, 263, 194.
3.7.11. Synthesis of 11-(40-(N-(4-chlorophenyl)-a-phenyl
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives
(MJ10)
A solution of 11-(piperazinyl)-dibenz[b,f][1,4]-oxazepine (7)
(2.8 gm, 0.010 mol) and tri-ethyl amine (1.5 gm, 0.015 mol) in
30 ml dioxane was taken. The reaction mixture was heated
to reﬂux and a solution of N-4-chlorophenyl-a-chlorophenyl
acetamide (2.80 gm, 0.01 mol) in 20 ml dioxane was added
with stirring. m.p. 186–88 C. Yield= 3.2 g (62.50%). IR
cm1: 3380 (–NH), 1693 (C‚O), 1590 (–NH), 1H NMR d:
2.15 (s, 1H, CH), 2.58 (t, 4H, 2CH2), 3.52 (t, 4H, 2CH2), 5.1
(s, 1H, NH), 6.8–6.7 (m, 4H, Ar-H), 7.1 (s, 5H, Ar-H), 7.25–
7.14 (d, 4H, Ar-H), 7.38–7.3 (m, 4H, Ar-H), 13C NMR d:
44.8, 48.7, 64.3, 111.3, 119.3, 120.8, 122.8, 123.7, 124.8,
125.9, 126.2, 127.4, 128.3, 130.4, 134.3, 135.8, 137.5, 139.5,
144.2, 149.3, 156.3, 159.8, 174.6, m/z 524(M), 522, 279, 263,
237, 223, 194.
3.7.12. Synthesis of 11-(40-(N-(4-methoxyphenyl)-a-phenyl
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives
(MJ11)
A solution of 11-(piperazinyl)-dibenz[b,f][1,4]-oxazepine (7)
(2.8 gm, 0.010 mol) and tri-ethyl amine (1.5 gm, 0.015 mol) in
30 ml dioxane was taken. The reaction mixture was heated
to reﬂux and a solution of N-4-methoxyphenyl-a-chlorophenyl
acetamide (2.75 gm, 0.01 mol) in 20 ml dioxane was added
with stirring. m.p. 240–42 C. Yield= 3.10 g (61%). IR
cm1: 3428 (–NH), 1657 (C‚O), 1598 (–NH), 1H NMR d:
2.3 (s, 1H, CH), 3.25 (s, 3H, CH3), 2.82 (t, 4H, 2CH2), 3.7
(t, 4H, 2CH2), 5.32 (s, 1H, NH), 7.2–6.8 (m, 9H, Ar-H),
7.36–7.2.4 (d, 4H, Ar-H), 7.5–7.4 (m, 4H, Ar-H), 13C NMR
d: 46.1, 49.8, 53.8, 66.2, 110.4, 117.8, 121.2, 122.7, 123.6,
124.6, 126.3, 127.4, 128.7, 129.4, 134.3, 135.7, 136.9, 140.5,
143.8, 147.5, 154.3, 157.1, 159.7, 172.4, m/z 519 (M+1), 502,
397, 368, 278, 263,1 194, 121.n of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-
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Synthesis and evaluation of antipsychotic activity 53.7.13. Synthesis of 11-(40-(N-(2,5-dichlorophenyl)-a-phenyl
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives
(MJ12)
A solution of 11-(piperazinyl)-dibenz[b,f][1,4]-oxazepine (7)
(2.8 gm, 0.010 mol) and tri-ethyl amine (1.5 gm, 0.015 mol) in
30 ml dioxane was taken. The reaction mixture was heated
to reﬂux and a solution of N-2,5-dichlorophenyl-a-chloro-
phenyl acetamide (3.15 gm, 0.01 mol) in 20 ml dioxane was
added with stirring. m.p. 238–40 C. Yield= 3.8 g (68.60%).
IR cm1: 3364 (–NH), 1659 (C‚O), 1600 (–NH), 1H NMR
d: 2.19 (s, 1H, CH), 2.66 (t, 4H, 2CH2), 3.66 (t, 4H, 2CH2),
5.19 (s, 1H, NH), 7.19 (s, 5H, Ar-H), 7.28–7.2 (m, 4H, Ar-
H), 7.5–7.4 (m, 2H, Ar-H), 7.79 (s, 1H, Ar-H), 13C NMR d:
45.4, 48.9, 64.3, 109.8, 116.9, 120.9, 121.8, 123.2, 124.4,
126.1, 127.3, 128.4, 129.6, 131.4, 133.6, 135.3, 137.7, 139.8,
145.2, 148.9, 154.4, 158.3, 173.8, m/z 558 (M), 556, 368, 279,
263, 237, 223, 194.
3.8. Pharmacological screening
For pharmacological screening catalepsy and foot shock in-
duced aggression model were used.
Catalepsy was induced by targeted compounds (MJ1–12)
and haloperidol at a dose of 5 mg/kg (i.p.) to mice (n= 5).
The duration of catalepsy was measured at 0, 30, 60, 90,
120, 150 and 180 min intervals by means of Bar test. Both
the forepaws of mouse were placed on a horizontal bar raised
3 cm from the table, and time required to remove the forepaws
from the bar was recorded as the duration of catalepsy. Foot
shock induced aggression was used for the anti aggression
activity, ﬁve pairs of mice were used to determine the activity
of individual compound. Each pair of mice was dosed withNO2H3COOC
HO
+
H3
O
N N
NH
N C OR
Cl
O
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Scheme 1 Synthetic pathway for synthesis of diben
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pounds (MJ1–12) and standard compound (clozapine) were
administered three min before the mice were placed in box with
grid ﬂoor consisting copper wire with a distance of 6 mm. A
constant current of 1.2 mA was supplied through grid by a
constant current shocker. Latency for ﬁrst attack and number
of total attack were determined for the total duration of 5 min.
All observations were given as mean ± SEM for each group.
The data were analyzed by One-way ANOVA followed by
Dunnett’s test, p< 0.05 was considered as signiﬁcant.
4. Results and discussion
4.1. Chemistry
Synthesis of the titled compounds (MJ1–MJ12) has been car-
ried out as being depicted in (Scheme 1). The condensation of
O-ﬂuoro nitro benzene with methyl salicylate in the presence of
potassium carbonate in lead nucleus was found to be superior
over Ulmman condensation as per the literature. Only slight
excess of methyl salicylate was enough for the complete utiliza-
tion of O-ﬂuoro nitro benzene and after the completion of
reaction the excess of methyl salicylate was removed by wash-
ing with cold 5% caustic solution. The reaction afforded 85–
90% yield and product was sufﬁciently pure for next step.
Scale up of this process was very easy due to controllable exo-
thermicity of the reaction and no pressure requirement with
much lesser reaction time. Catalytic hydrogenation process
was utilized in next step to avoid hydrolysis of ester group. Ni-
tro diphenyl ether (3) was hydrogenated to amino diphenyl
ether (4) using raney-nickel as catalyst and methanol as solvent
at 3 kg hydrogen pressure and subsequently the same materialO
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Figure 3 Effect of compounds MJ7, MJ8, MJ9, MJ10, MJ11
and MJ12 on latency to ﬁghts in foot shocked induced aggression
in mice.
6 M.S. Jain, S.J. Suranawas used for next step of cyclization. The cyclization process
was carried out in DMF and initiated by catalytic amount of
sulfuric acid to get lactam (5). Activation of tricyclic lactam
to the corresponding imino chloride was done by reaction with
excess phosphorous oxychloride at reﬂux temperature for 8 h.
Tricyclic imino chloride was puriﬁed by high vacuum distilla-
tion at 160–162 C and 2 mmHg vacuum. To avoid dimeriza-
tion the puriﬁed 11-chloro dibenzoxazepine is then
condensed with excess of anhydrous piperazine. The excess
of piperazine was removed by water washing to get lead nu-
cleus 11-piperazinyl dibenzoxzepine.
While in side chain synthesis as per the literature report lin-
ker group between N4 and aryl moiety must be two to four
atoms. The carboxamido analogues (MJ1–6) were furnished
from highly reactive aryl isocynate and lead nucleus. In the
synthesis of aryl isocyante derivatives the direct use of phos-
gene gas is highly dangerous, to avoid risk of phosgene gas
handling triphogene was used which is in situ converted into
phosgene gas by heating at 60 C in the presence of substituted
aniline hydrochoride to get aryl isocyanate in 55–75% yield.
The N-aryl-a-chlorophenyl acetamide analogues were syn-
thesized by reacting lead nucleus with different N-aryl-a-chlo-n = 6, * P < 0.05 One-way ANOVA followed by dunnett's test
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Figure 2 Effect of compounds MJ1, MJ2, MJ3, MJ4, MJ5 and
MJ6 on number of ﬁghts in foot shocked induced aggression in
mice.
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Figure 1 Effect of compounds MJ1, MJ2, MJ3, MJ4, MJ5 and
MJ6 on latency to ﬁghts in foot shocked induced aggression in
mice.
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12) with 45–71% yield. Chirality in molecule is helpful to re-
duce enzymatic decomposition of one enantiomer. While theFigure 4 Effect of compounds MJ7, MJ8, MJ9, MJ10, MJ11
and MJ12 on number of ﬁghts in foot shocked induced aggression
in mice.
Table 1 Foot shock induced treatment data of compounds
MJ1–12.
Treatment (5 mg/kg, i.p.) Latency to ﬁght (s) Number of ﬁght
Vehicle 16.4 56
Clozapine 189 13.4
MJ1 167.4 12.8
MJ2 78.2 33.8
MJ3 173 14.2
MJ4 181.8 8.4
MJ5 144 29
MJ6 75.2 28
MJ7 136.4 13.2
MJ8 94.2 18.8
MJ9 111.6 22.2
MJ10 84.2 23.2
MJ11 92.4 23.6
MJ12 120 16.4
n of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-
of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.033
Figure 5 Effect of compounds MJ1–MJ12 on catalepsy in mice.
Table 2 Duration of catalepsy induced by compounds MJ1–12.
Treatment 0 30 60 90 120 min 150 180 min
Duration of catalepsy in secs (Mean ± SEM)
Haloperidol 0.01 116.6 160.6 191.6 193.3 281.6 198.3
MJ1 2.4 17.5 21.5 25 29.2 30.5 24.2
MJ2 1.6 8.5 12.6 18.4 20.2 17.2 19.6
MJ3 2.8 5.4 19.4 22.3 20.2 25.3 27.2
MJ4 2.3 12.6 20.3 24.6 25 28.3 22.6
MJ5 2.8 19.5 28.5 24.9 28.2 28.5 26.3
MJ6 1.8 7.8 12.4 21.3 19.2 23.3 22.2
MJ7 2.3 11.6 38.3 31.6 25 28.6 24.8
MJ8 1.8 8.5 17.6 20.8 22.7 24.2 23.2
MJ9 1.4 6.6 18.4 21.3 20.2 26.3 28.2
MJ10 2.5 16.2 24.1 33.4 28.2 31.7 38.1
MJ11 2.1 15.5 22.5 22.4 24.2 27.2 24.6
MJ12 1.2 3.3 19.6 21.6 21.6 20.2 24.2
Synthesis and evaluation of antipsychotic activity 7phenyl ring at a position creates steric hindrances which helps
to reduce metabolic oxidation of molecule ultimately leading
to better metabolic stability with prolonged biological half life.
The IR spectra of carboxamido derivative (MJ1–6) and N-
aryl-a-chlorophenyl acetamide derivative (MJ7–12) revealed
absorption bands in the region of 1700–1650 cm1 correspond-
ing to amide (NH–C‚O) stretching vibration in IR region
which is not present in lead nucleus conforming the formation
of ﬁnal compounds. In 1H NMR deuterium exchange conﬁrms
the formation of lead nucleus. Presence of amide proton in 1H
NMR spectrum at 6.4–5.1 (d ppm) conﬁrms the formation of
ﬁnal compounds.
4.2. Antipsychotic activity
In pharmacological screening, all newly synthesized com-
pounds showed reduction in number of ﬁghts and increase in
latency to ﬁght in foot shocked induced aggression model
suggesting antipsychotic activity of the compounds (Fig. 1–4,Please cite this article in press as: Jain, M.S., Surana, S.J. Synthesis and evaluatio
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives. Arabian JournalTable 1). In addition all compounds were unable to produce
catalepsy in mouse indicating compounds without extrapyra-
midal effect (Fig. 5, Table 2). It clearly demonstrated that,
all newly synthesized compounds are like atypical antipsy-
chotic drugs with decreased metabolic deactivation which is
a prominent factor for bioavailability of drugs. Study showed
that ring substitution is not required for antipsychotic activity.
Strong electron withdrawing N-aryl carboxamido side chain
showed better activity than sterically hindered N-aryl a-phenyl
acetamido group. Para substitution on side chain aryl group
showed better activity than ortho substitution and chloro
group at para position (MJ4) showed better activity than
methyl or methoxy group.
5. Conclusion
In summary, we have reported simple, high yielding synthesis
of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-acetamido)-
piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives. Antipsychoticn of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-
of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.033
8 M.S. Jain, S.J. Suranaevaluation was done for compounds by foot shock induced
aggression in mice and shown good to equipotent activities.
In future, receptor speciﬁc in vitro evaluation of these com-
pounds can also be carried out for further study.Acknowledgments
The authors duly acknowledge the support from Dr. Anil Tati-
ya, Dr. Bhavin Vyas, Sandesh Lodha and Pravin Patil for their
valuable support during study period. Authors gratefully
acknowledge NHRDF Nasik, Hikal Ltd Pune for spectral
data.
References
Burki, H.R., Sayers, A.C., Ruch, W., Asper, H., 1975. Clozapine and
the dopamine hypothesis of schizophrenia a critical appraisal.
Pharmacopsychiatry 8, 115–121.
Capuano, B., Crosby, I.T., Lloyd, E.J., Podloucka, A., Taylor, D.A.,
2003. Synthesis and preliminary pharmacological evaluation of 4’-
arylalkyl analogue of clozapine. II. Effect of the nature and length
of the linker. Aust. J. Chem. 56, 875–886.
Chakrabarti et al, 1980. 4-Piperazinyl-10H-thieno[2,3-b][1,5] benzodi-
azepines as potential neuroleptic. J. Med. Chem. 23 (8), 878–884.
Alvir, Jose M.J., Lieberman, Jeffrey A., Safferman, Allan Z., Schw-
immer, Jeffrey L., Schaaf, John A., 1993. Clozapine-induced
agranulocytosis incidence and risk factors in the United States. N
Engl J Med 329, 162–167.Please cite this article in press as: Jain, M.S., Surana, S.J. Synthesis and evaluatio
acetamido)-piperazinyl)-dibenz[b,f][1,4]-oxazepine derivatives. Arabian JournalKane, J.M., Cooper, T.B., Sachar, E.J., Halpern, F.S., Bailine, S.,
1981. Clozapine: plasma levels and prolactin response. Psycho-
pharmacology 73, 184–187.
Lieberman, J.A., Kane, J., Johns, C.A., Vital-Herne, J., 1986.
Clozapine: clinical evidence of novel effects. Clin. Neuropharma-
col. 9 (4), 140–141.
Lieberman, J.A., Saltz, B.L., Johns, C.A., Pollack, S., Kane, J.M.,
1989. Clozapine effects on tardive dyskinesia. Psychopharmacol.
Bull. 25, 57–62.
Sayers, A.C., Burki, H.R., Ruch, W., Asper, H., 1975. Neuroleptic-
induced hypersensitivity of striatal dopamine receptors in the rat as
a model of tardive dyskinesias effects of clozapine, haloperidol,
loxapine and chlorpromazine. Psychopharmacologia 41, 97–104.
Stutton, B.M., 1969. U.S.Pat., 347182.
Smits, R.A., Lim, H.D., Stegink, B., 2006. Characterization of the
histamine H4 receptor binding site. Part I. Synthesis and pharma-
cological evaluation of dibenzodiazepine derivatives. J. Med.
Chem. 49, 4512–4516.
The World Health Report 2001 Mental health: new understanding,
new hope. World Health Organization: Geneva.
Work group on schizophrenia, 1997. Practice guideline for the
treatment of patient with schizophrenia. Am. J. Psychiatry 153,
1–63.
Wagh, B.S., Patil, B.P., Jain, M.S., Harak, S.S., Wagh, S.B., 2007.
Heterocyclic Commun. 13, 2–3.
Wagh, S.B., Patil, B.P., Yerande, S.W., 2005. Synthesis and evaluation
of antipsychotic activity of 8-chloro-11-(4-aryl-1-piperazinyl)-
dibenz[b,f][1,4] oxazepines. Indian Patent, 365/MUM/05.n of antipsychotic activity of 11-(40-(N-aryl carboxamido/N-aryl-a-phenyl-
of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.07.033
